USD 0.0
(0.0%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2022 | 110.87 Million USD | -44.82% |
2021 | 200.91 Million USD | 77.91% |
2020 | 112.92 Million USD | -57.9% |
2019 | 268.26 Million USD | 312.99% |
2018 | 64.95 Million USD | 526.84% |
2017 | -15.21 Million USD | 56.62% |
2016 | -35.08 Million USD | -17.69% |
2015 | -29.8 Million USD | 50.12% |
2014 | -59.75 Million USD | -122.46% |
2013 | -26.86 Million USD | -427.6% |
2012 | -5.09 Million USD | -46.87% |
2011 | -3.46 Million USD | 34.32% |
2010 | -5.27 Million USD | -53.87% |
2009 | -3.42 Million USD | -801.52% |
2008 | -380.46 Thousand USD | -1638.93% |
2007 | -21.87 Thousand USD | 0.0% |
2006 | - USD | 0.0% |
2005 | - USD | -100.0% |
2004 | 9537.00 USD | 0.0% |
2003 | 9537.00 USD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 Q1 | 131.89 Million USD | 18.96% |
2023 Q2 | 137.85 Million USD | 4.52% |
2022 Q4 | 110.87 Million USD | 13.68% |
2022 Q1 | 136.97 Million USD | -31.82% |
2022 FY | 110.87 Million USD | -44.82% |
2022 Q3 | 97.52 Million USD | -27.36% |
2022 Q2 | 134.26 Million USD | -1.98% |
2021 Q4 | 200.91 Million USD | 23.4% |
2021 Q1 | 113.08 Million USD | 0.14% |
2021 Q2 | 87.45 Million USD | -22.67% |
2021 Q3 | 162.82 Million USD | 86.18% |
2021 FY | 200.91 Million USD | 77.91% |
2020 Q4 | 112.92 Million USD | -23.56% |
2020 Q3 | 147.73 Million USD | -24.8% |
2020 Q2 | 196.45 Million USD | -15.73% |
2020 Q1 | 233.11 Million USD | -13.1% |
2020 FY | 112.92 Million USD | -57.9% |
2019 FY | 268.26 Million USD | 312.99% |
2019 Q2 | 248.9 Million USD | 26.01% |
2019 Q4 | 268.26 Million USD | -4.87% |
2019 Q1 | 197.53 Million USD | 164.97% |
2019 Q3 | 281.99 Million USD | 13.29% |
2018 Q2 | -29.07 Million USD | -69.44% |
2018 Q4 | 74.54 Million USD | 94.52% |
2018 FY | 64.95 Million USD | 526.84% |
2018 Q1 | -17.15 Million USD | -12.74% |
2018 Q3 | 38.32 Million USD | 231.84% |
2017 FY | -15.21 Million USD | 56.62% |
2017 Q1 | -7.83 Million USD | 77.66% |
2017 Q2 | -27.14 Million USD | -246.35% |
2017 Q3 | -11.34 Million USD | 58.21% |
2017 Q4 | -15.21 Million USD | -34.19% |
2016 FY | -35.08 Million USD | -17.69% |
2016 Q1 | -12.75 Million USD | 57.22% |
2016 Q2 | -91.31 Million USD | -616.11% |
2016 Q3 | -60.83 Million USD | 33.38% |
2016 Q4 | -35.08 Million USD | 42.33% |
2015 FY | -29.8 Million USD | 50.12% |
2015 Q2 | -40.21 Million USD | 16.75% |
2015 Q1 | -48.3 Million USD | 19.16% |
2015 Q3 | -48.69 Million USD | -21.09% |
2015 Q4 | -29.8 Million USD | 38.79% |
2014 Q2 | -38.1 Million USD | -112.33% |
2014 Q3 | -32.16 Million USD | 15.58% |
2014 FY | -59.75 Million USD | -122.46% |
2014 Q4 | -59.75 Million USD | -85.76% |
2014 Q1 | -17.94 Million USD | 33.19% |
2013 Q4 | -26.86 Million USD | -1533.55% |
2013 FY | -26.86 Million USD | -427.6% |
2013 Q2 | -4.92 Million USD | 43.77% |
2013 Q1 | -8.76 Million USD | -72.11% |
2013 Q3 | -1.64 Million USD | 66.63% |
2012 Q2 | -7.62 Million USD | -212.07% |
2012 Q4 | -5.09 Million USD | 21.01% |
2012 Q3 | -6.44 Million USD | 15.47% |
2012 FY | -5.09 Million USD | -46.87% |
2012 Q1 | -2.44 Million USD | 29.51% |
2011 Q1 | -4.71 Million USD | 10.68% |
2011 Q4 | -3.46 Million USD | -52.68% |
2011 Q3 | -2.27 Million USD | 22.31% |
2011 Q2 | -2.92 Million USD | 38.01% |
2011 FY | -3.46 Million USD | 34.32% |
2010 Q3 | -1.96 Million USD | 9.75% |
2010 FY | -5.27 Million USD | -53.87% |
2010 Q2 | -2.17 Million USD | 18.79% |
2010 Q4 | -5.27 Million USD | -168.48% |
2010 Q1 | -2.68 Million USD | 21.81% |
2009 FY | -3.42 Million USD | -801.52% |
2009 Q1 | -364.53 Thousand USD | 4.18% |
2009 Q2 | -291.67 Thousand USD | 19.99% |
2009 Q3 | -3.95 Million USD | -1255.89% |
2009 Q4 | -3.42 Million USD | 13.27% |
2008 Q1 | -17.13 Thousand USD | 21.67% |
2008 FY | -380.46 Thousand USD | -1638.93% |
2008 Q4 | -380.46 Thousand USD | 8.69% |
2008 Q3 | -416.65 Thousand USD | -2004.37% |
2008 Q2 | 21.87 Thousand USD | 227.66% |
2007 Q1 | -75.45 Thousand USD | 0.0% |
2007 Q3 | -30.01 Thousand USD | 29.8% |
2007 Q4 | -21.87 Thousand USD | 27.1% |
2007 Q2 | -42.75 Thousand USD | 43.34% |
2007 FY | -21.87 Thousand USD | 0.0% |
2006 FY | - USD | 0.0% |
2006 Q2 | - USD | 0.0% |
2006 Q4 | - USD | 0.0% |
2006 Q3 | - USD | 0.0% |
2006 Q1 | - USD | 0.0% |
2005 Q1 | 9537.00 USD | 0.0% |
2005 Q4 | - USD | -100.0% |
2005 Q3 | 9537.00 USD | 0.0% |
2005 Q2 | 9537.00 USD | 0.0% |
2005 FY | - USD | -100.0% |
2004 Q1 | 9537.00 USD | 0.0% |
2004 Q3 | 9537.00 USD | 0.0% |
2004 FY | 9537.00 USD | 0.0% |
2004 Q2 | 9537.00 USD | 0.0% |
2004 Q4 | 9537.00 USD | 0.0% |
2003 FY | 9537.00 USD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
America Great Health | 1.81 Million USD | -6004.766% |
Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 3006.16% |
Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -8741.308% |
Biora Therapeutics, Inc. | 32.21 Million USD | -244.156% |
Bio-Path Holdings, Inc. | -939 Thousand USD | 11907.242% |
Better Therapeutics, Inc. | -860 Thousand USD | 12991.86% |
Calithera Biosciences, Inc. | -23.78 Million USD | 566.134% |
Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -33656.443% |
Gene Biotherapeutics, Inc. | - USD | -Infinity% |
eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -2326.039% |
Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 2004.001% |
Evelo Biosciences, Inc. | 3.19 Million USD | -3366.854% |
Evolutionary Genomics, Inc. | 3.16 Million USD | -3401.142% |
Finch Therapeutics Group, Inc. | 5 Million USD | -2116.513% |
Galera Therapeutics, Inc. | 134.04 Million USD | 17.287% |
Innovation1 Biotech Inc. | 179.15 Thousand USD | -61786.687% |
Kiromic BioPharma, Inc. | 12.33 Million USD | -798.57% |
Molecular Templates, Inc. | 707 Thousand USD | -15581.754% |
Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | -25187.152% |
NexImmune, Inc. | -3.13 Million USD | 3638.055% |
Orgenesis Inc. | 21.78 Million USD | -408.952% |
Panbela Therapeutics, Inc. | 2.61 Million USD | -4138.15% |
Point of Care Nano-Technology, Inc. | -498.00 USD | 22263152.209% |
PaxMedica, Inc. Common Stock | -4.71 Million USD | 2453.607% |
Scopus BioPharma Inc. | -124.57 Thousand USD | 89098.595% |
Statera Biopharma, Inc. | 14.41 Million USD | -669.054% |
TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 1559.584% |
Trevena, Inc. | 2.25 Million USD | -4810.097% |
Vaxxinity, Inc. | 10.13 Million USD | -994.256% |
Vaccinex, Inc. | -1.28 Million USD | 8707.919% |
Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | -32087.919% |
Viracta Therapeutics, Inc. | 13.23 Million USD | -737.45% |
ZIVO Bioscience, Inc. | 71.96 Thousand USD | -153967.424% |